Dimethylamine

Dimethylamine

SCHEMBL2580728

CNC.O=C(C1=NOC2(CCN(S(=O)(=O)O)CC2)C1)N1CCN(CCCc2ccccc2)CC1

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 7/20 0.44
FAAH O00519 1/20 0.43
KDM4E B2RXH2 3/20 0.43
ALDH1A1 P00352 3/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
ALOX15 P16050 1/20 0.43
LMNA P02545 1/20 0.41
HTR2A P28223 2/20 0.40
OPRM1 P35372 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HTR1A P08908 1/20 0.40
DRD4 P21917 1/20 0.40
HRH1 P35367 1/20 0.40
KCNH2 Q12809 1/20 0.40
ADORA3 P0DMS8 1/20 0.39
HTR7 P34969 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2403239 0.88 MEN1 (0.47) SIGMAR1FAAHKDM4EALDH1A1MEN1
SCHEMBL2403707 0.88 SIGMAR1 (0.46) SIGMAR1FAAHKDM4EALDH1A1MEN1
SCHEMBL2581274 0.84 F13A1 (0.46) SIGMAR1KDM4EALDH1A1MEN1KMT2A
SCHEMBL2574163 0.83 PKM (0.50) SIGMAR1KDM4EALDH1A1MEN1KMT2A
SCHEMBL2403271 0.81 GAA (0.50) SIGMAR1ALDH1A1MEN1KMT2ALMNA
SCHEMBL2402061 0.80 KMT2A (0.45) SIGMAR1KDM4EALDH1A1MEN1KMT2A
Formamide SCHEMBL6417823 0.73 KMT2A (0.43) FAAHMEN1KMT2A
SCHEMBL2401137 0.71 TRPV4 (0.49) KDM4EALDH1A1KMT2ALMNA
SCHEMBL2400362 0.71 GAA (0.65) ALDH1A1KMT2ALMNASMN1; SMN2
SCHEMBL2401405 0.71 TSHR (0.46) ALDH1A1KMT2ALMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8048890-B2 Analgesics; neuropathic pain; headaches; muscle relaxants; incontence; tinnitus; diarrhea; antiarrhythmia agents; antiischemic agents; antiinflammatory agents; antiulcer agents; antidepressants; antiepileptic agents GRUENENTHAL GMBH (DE) 2011-11-01 US disclosed
US-20040192916-A1 Substituted 1-oxa-2,8-diaza-spiro[4,5]dec-2-ene derivatives and related treatment methods GRUENENTHAL GMBH (DE) 2004-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192916-A1 Substituted 1-oxa-2,8-diaza-spiro[4,5]dec-2-ene derivatives and related treatment methods SULT1E1, CYP4B1, CYP3A4 SIGMAR1 2326/4885FAAH 4794/4885KDM4E 67/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.